XML 41 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Assets and Liabilities Measured at Fair Value      
Transfer of assets from Level 1 to Level 2 $ 0    
Transfer of assets from Level 2 to Level 1 0    
Assets:      
Derivative asset 2,238    
Fair value of assets 482,892   $ 311,700
Liabilities:      
Contingent consideration payable 26,500   25,400
Derivative liability 80,577    
Deferred compensation plan liability 2,491   2,258
Fair value of liabilities 109,568   27,658
Fair value of the debt 642,300    
Contingent consideration payable      
Balance, beginning of the period 25,400 $ 269,722  
Changes in fair value during the period, included in Statement of Operations 1,100 4,578  
Balance, end of the period 26,500 $ 274,300  
Clinical and Regulatory Approval milestones | Callidus      
Liabilities:      
Contingent consideration payable 26,000    
Commercial paper      
Assets:      
Fair value of assets 121,860   79,803
Asset-backed securities      
Assets:      
Fair value of assets 47,828   30,287
Corporate debt securities      
Assets:      
Fair value of assets 308,125   199,012
Money market funds      
Assets:      
Fair value of assets 2,841   2,598
Level 2      
Assets:      
Fair value of assets 480,654   311,700
Liabilities:      
Deferred compensation plan liability 2,491   2,258
Fair value of liabilities 2,491   2,258
Level 2 | Commercial paper      
Assets:      
Fair value of assets 121,860   79,803
Level 2 | Asset-backed securities      
Assets:      
Fair value of assets 47,828   30,287
Level 2 | Corporate debt securities      
Assets:      
Fair value of assets 308,125   199,012
Level 2 | Money market funds      
Assets:      
Fair value of assets 2,841   2,598
Level 3      
Assets:      
Derivative asset 2,238    
Fair value of assets 2,238    
Liabilities:      
Contingent consideration payable 26,500   25,400
Derivative liability 80,577    
Fair value of liabilities $ 107,077   $ 25,400
Level 3 | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus      
Liabilities:      
Discount rate (as a percent) 11.00%    
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus      
Liabilities:      
Probability of achievement of milestones (as a percent) 71.00%    
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus      
Liabilities:      
Probability of achievement of milestones (as a percent) 100.00%